All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

asunaprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
Hepatitis Virus C (HVC) protease inhibitors	4889	630420-16-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: asunaprevir BMS-650032 sunvepra	an NS3 protease inhibitor against hepatitis C virus Molecular weight: 748.29 Formula: C35H46ClN5O9S CLOGP: 5.67 LIPINSKI: 3 HAC: 14 HDO: 3 TPSA: 182.33 ALOGS: -5.40 ROTB: 13

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	2.77 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11.78 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	20 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	EIF2AK3,GRK2,PDK1,PDK2,PDK4	5
kinase-selectivity-class	PDK1	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
July 4, 2014	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Alanine aminotransferase increased	84.88	53.89	30	495	118308	90509614

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Alanine aminotransferase increased	91.46	45.43	39	838	183734	110404688
Hepatocellular carcinoma	80.13	45.43	18	859	9862	110578560
Hepatic function abnormal	68.76	45.43	26	851	89269	110499153
Pyrexia	59.67	45.43	52	825	898213	109690209
Ascites	57.19	45.43	23	854	92785	110495637
Hepatitis B DNA increased	55.77	45.43	9	868	846	110587576
Renal impairment	53.01	45.43	27	850	188418	110400004

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AP06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
ATC	J05AP58	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors

Related Drugs by ATC class:

J05AP Antivirals for treatment of HCV infections 18 drugs

beclabuvirboceprevirdaclatasvirdasabuvirelbasvirglecaprevirgrazoprevirledipasvirombitasvirparitaprevirpibrentasvirribavirin show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.1	acidic
pKa2	1.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Genome polyprotein	Polyprotein		POLG_HCVH	INHIBITOR	Ki	9.40		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Integrase	Enzyme		Q7ZJM1_9HIV1		IC50	9		CHEMBL
NS3	Enzyme		A3EZI9_9HEPC		EC50	8.92		CHEMBL
Genome polyprotein	Polyprotein		A3EZJ3_9HEPC		EC50	8.92		CHEMBL

External reference:

ID	Source
S9X0KRJ00S	UNII
D10093	KEGG_DRUG
C3491974	UMLSCUI
2R9	PDB_CHEM_ID
CHEMBL2105735	ChEMBL_ID
16076883	PUBCHEM_CID
DB11586	DRUGBANK_ID
9472	INN_ID
C571889	MESH_SUPPLEMENTAL_RECORD_UI
10882	IUPHAR_LIGAND_ID
1652103	RXNORM
016060	NDDF
715390003	SNOMEDCT_US
CHEBI:134723	CHEBI
S9X0KRJ00S	INXIGHT DRUGS

Pharmaceutical products:

None